Medtronic MiniMed 670G

Price Guarantee
Our Price
Lower Price in Cart

    See lower price in cart

This product is not currently available.
Promotion information
$10 Off $75+ PLUS FREE Shipping over $49. Offers end Midnight TONIGHT. Details
SAVE on Cure Ultra Cath for Men.  Shop Now!
SAVE on NEW Cure Ultra For Men Ready-To-Use Cath. Shop Now!.
Other Options

Product Overview

Minimed Medtronic MiniMed 670G

MiniMed 670G Automated Insulin Delivery System

Medtronic’s MiniMed 670G has just received approval by the US Food and Drug Administration as a medical device that monitors a diabetic’s sugar levels, and then automatically injects the required dose of insulin. The MiniMed 670G automated insulin delivery system is the first-of-its kind to be approved for people over the age of 14 who have type 1 diabetes, and it will certainly make life considerably better for the millions of American suffers with this condition. People with type 1 diabetes can’t produce the insulin needed by their bodies. Insulin is the a hormone that regulates the amount of glucose, or sugar, in our blood. Diabetics must replenish their insulin stock either with multiple daily injections, or by pumping insulin through a tiny catheter tube. Unlike the traditional manual techniques, the Medtronic MiniMed 670G is a “hybrid closed system,” meaning it autonomously tracks glucose levels about every five minutes or so, and then adjusts insulin levels with little or no input from the user. “[MiniMed 670G] can provide people with type 1 diabetes greater freedom to live their lives without having to consistently and manually monitor baseline glucose levels and administer insulin,” the FDA’s Jeffrey Shuren said in a release. MiniMed 670G includes a sensor that attaches to the body to measure glucose levels under the skin, an insulin pump that’s strapped to the body, and a catheter that delivers the insulin. The insulin delivery site needs to be changed about twice a week. The device has been referred to as an “artificial pancreas,” but that’s probably not the best description. The device is not an internal organ, and it’s not completely autonomous. People with type 1 diabetes still need to track their carbohydrate intake, and then enter that information into the system. The FDA approved Medtronic’s MiniMed 670G following a successful clinical trial that included 123 participants with type 1 diabetes. During the course of the three-month trial, no serious or adverse effects—such as diabetic ketoacidosis (DKA) or severe hypoglycemia (low glucose levels—were reported. Medtronic, a medical tech firm based in Dublin, Ireland, says the device will be made available to the public in the spring of 2017. Looking ahead, the company plans to refine and further test the device in the hope that children under of the age of 14 can also use it.

Medtronic MiniMed 670G Reviews Summary

Allegro Medical does not endorse, recommend or sponsor any customer product reviews, ideas or advice.
Average Rating
0 reviews
Stacked Stars
Question and Answer
Medtronic MiniMed 670G
Ask the community about this product and get answers. Share your knowledge and advice. Learn More about Q&A.
Q and A Hands
0 Questions | 0 Answers
Ask Question

Part Number(s): TSI70725

Scrip Part Number(s):